Needham Maintains Buy on Avadel Pharmaceuticals, Raises Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a Buy rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and raises the price target from $18 to $19.
November 09, 2023 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst maintains a Buy rating on Avadel Pharmaceuticals and raises the price target from $18 to $19.
The news of Needham maintaining a Buy rating and raising the price target for Avadel Pharmaceuticals is likely to instill confidence in investors and could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100